Form 4: OrbiMed Advisors Sells NeuroPace Inc (NPCE) Shares

OrbiMed Advisors LLC, a significant shareholder of NeuroPace Inc, has sold a portion of its common stock holdings in two transactions on April 11 and 12, 2024.

Summary

• OrbiMed Advisors LLC, along with OrbiMed Capital GP VI LLC, filed a Form 4 detailing changes in beneficial ownership of NeuroPace Inc (NPCE) stock.
• On April 11, 2024, OrbiMed sold 461,899 shares of common stock at a weighted average price of $14.49 per share.
• The price range for the April 11th sale was between $14.47 and $14.66.
• On April 12, 2024, an additional 23,101 shares were sold at $14.42 per share.
• Following these transactions, OrbiMed's indirect beneficial ownership stands at 3,518,967 shares.
• OrbiMed Advisors disclaims beneficial ownership of the securities except to the extent of its pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales. It doesn't inherently convey positive or negative sentiment, but rather reports factual transactions.

Management Comments

• OrbiMed Advisors disclaims beneficial ownership of the securities reported except to the extent of its pecuniary interest.

Industry Context

This filing reflects activity by a major institutional investor in NeuroPace, a company in the neuromodulation space. Monitoring such transactions provides insights into investor sentiment and potential stock performance.

Comparison to Industry Standards

• It's common for large shareholders like OrbiMed to periodically adjust their holdings.
• Similar transactions can be observed with other healthcare companies where institutional investors manage significant stakes.
• The sale prices are within a normal range for stock transactions of this nature.

Stakeholder Impact

• The sale of shares by a major shareholder like OrbiMed could potentially influence investor confidence and the stock price of NeuroPace.

Key Dates